Senseonics Holdings Inc. (NASDAQ: SENS) stock declined by 9.19% at last close whereas the SENS stock price surged by 4.62% in the pre-market trading session. Senseonics Holdings, Inc. is a medical technology business that deals with the creation, production, and marketing of transformative glucose monitoring technologies that let people with diabetes live their lives with confidence and simplicity.
SENS stock’ Recent Development
The University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio has begun distributing the Eversense CGM System to its Medicare members as of early September 2021, according to Senseonics Holdings. UHACO’s recent decision to deploy the Eversense CGM System is suitable patients with type 1 diabetes or type 2 diabetes on insulin demonstrates its commitment to assisting its enrollees in achieving optimal diabetes management.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The University Hospitals Accountable Care Organization (UHACO) was founded in 2010 with the goal of improving the health and wellness of employees and their families who are enrolled in a UH employee medical plan.
Furthermore,
A fluorescence-based sensor, a savvy transmitter placed over the sensor to permit data exchange, and a mobile app for showing glucose readings, trends, and alarms make up the Eversense CGM System. The device is the first to include a smart transmitter that gives wearers unobtrusive on-body vibratory alerts for high and low glucose and can be withdrawn, recharged, and re-attached to the skin without abandoning the sensor, in addition to the first long-term and implantable CGM sensor. A health care professional inserts the sensor subcutaneously in the upper arm during a quick in-office procedure.
Betul Hatipoglu, Head of Endocrinology and Diabetes at UHACO stated,
They’re thrilled to be able to provide Eversense to their ACO diabetes patients. They can meet the American Diabetes Association’s Standards of Care for patients who use insulin by providing tools for optimal glucose management. Patients can choose from a variety of continuous glucose monitoring devices from Eversense. The Eversense CGM system provides industry-leading accuracy, a better patient experience, and a variety of unique features that enable people, particularly those on Medicare, to obtain better health results.
